Ritter Pharma (RTTR) and Qualigen Announce All-Stock Merger Agreement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Ritter Pharmaceuticals, Inc. and Qualigen, Inc. Announce Merger Agreement
January 21, 2020 9:15 AM ESTTransaction to Create a Nasdaq-listed Biotechnology Company Focused on Advancing Qualigens Cancer and Infectious Disease Therapeutic Development Programs
LOS ANGELES, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (Ritter Pharmaceuticals or the Company), a developer of therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, reported that it has entered into a definitive reverse merger agreement with Qualigen, Inc. (Qualigen), a privately-held company focused on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases, as well as expansion of its flagship... More
